GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADMA Biologics Inc (NAS:ADMA) » Definitions » Cyclically Adjusted PS Ratio

ADMA Biologics (ADMA Biologics) Cyclically Adjusted PS Ratio : 11.24 (As of May. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is ADMA Biologics Cyclically Adjusted PS Ratio?

As of today (2024-05-31), ADMA Biologics's current share price is $9.55. ADMA Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $0.85. ADMA Biologics's Cyclically Adjusted PS Ratio for today is 11.24.

The historical rank and industry rank for ADMA Biologics's Cyclically Adjusted PS Ratio or its related term are showing as below:

ADMA' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.72   Med: 4.19   Max: 11.25
Current: 11.21

During the past years, ADMA Biologics's highest Cyclically Adjusted PS Ratio was 11.25. The lowest was 1.72. And the median was 4.19.

ADMA's Cyclically Adjusted PS Ratio is ranked worse than
70.63% of 504 companies
in the Biotechnology industry
Industry Median: 5.425 vs ADMA: 11.21

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ADMA Biologics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.346. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.85 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


ADMA Biologics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for ADMA Biologics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADMA Biologics Cyclically Adjusted PS Ratio Chart

ADMA Biologics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.41 3.16 2.16 5.22 5.52

ADMA Biologics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.36 4.77 4.51 5.52 7.80

Competitive Comparison of ADMA Biologics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, ADMA Biologics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ADMA Biologics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ADMA Biologics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ADMA Biologics's Cyclically Adjusted PS Ratio falls into.



ADMA Biologics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

ADMA Biologics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=9.55/0.85
=11.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ADMA Biologics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, ADMA Biologics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.346/131.7762*131.7762
=0.346

Current CPI (Mar. 2024) = 131.7762.

ADMA Biologics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.161 100.560 0.211
201409 0.147 100.428 0.193
201412 0.160 99.070 0.213
201503 0.153 99.621 0.202
201506 0.122 100.684 0.160
201509 0.173 100.392 0.227
201512 0.242 99.792 0.320
201603 0.198 100.470 0.260
201606 0.187 101.688 0.242
201609 0.228 101.861 0.295
201612 0.258 101.863 0.334
201703 0.204 102.862 0.261
201706 0.207 103.349 0.264
201709 0.183 104.136 0.232
201712 0.265 104.011 0.336
201803 0.089 105.290 0.111
201806 0.109 106.317 0.135
201809 0.091 106.507 0.113
201812 0.087 105.998 0.108
201903 0.076 107.251 0.093
201906 0.126 108.070 0.154
201909 0.122 108.329 0.148
201912 0.203 108.420 0.247
202003 0.138 108.902 0.167
202006 0.090 108.767 0.109
202009 0.117 109.815 0.140
202012 0.144 109.897 0.173
202103 0.139 111.754 0.164
202106 0.140 114.631 0.161
202109 0.155 115.734 0.176
202112 0.146 117.630 0.164
202203 0.149 121.301 0.162
202206 0.173 125.017 0.182
202209 0.209 125.227 0.220
202212 0.246 125.222 0.259
202303 0.256 127.348 0.265
202306 0.270 128.729 0.276
202309 0.299 129.860 0.303
202312 0.327 129.419 0.333
202403 0.346 131.776 0.346

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


ADMA Biologics  (NAS:ADMA) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


ADMA Biologics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of ADMA Biologics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


ADMA Biologics (ADMA Biologics) Business Description

Traded in Other Exchanges
N/A
Address
465 State Route 17, Ramsey, NJ, USA, 07446
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Executives
Alison Cecily Finger director C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Jerrold B Grossman director 65 COMMERCE WAY, HACKENSACK NJ 07601
Young Kwon director C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Bryant Fong director 2170 VALLEJO STREET #101, SAN FRANCISCO CA 94123
Adam S Grossman director, officer: President and CEO 65 COMMERCE WAY, HACKENSACK NJ 07601
Brian Lenz officer: EVP, CFO 65 COMMERCE WAY, HACKENSACK NJ 07601
Lawrence P. Guiheen director 65 COMMERCE WAY, HACKENSACK NJ 07601
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
James Mond officer: CSO/CMO 65 COMMERCE WAY, HACKENSACK NJ 07601
Biotest Divestiture Trust 10 percent owner C/O ERIC ROSENBACH, TRUSTEE, 402 NORFOLK STREET, CAMBRIDGE MA 02139
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric I Richman director C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854
Biotest Pharmaceuticals Corp director, 10 percent owner 5800 PARK OF COMMERCE BLVD., NW, BOCA RATON FL 33487